Absci Corp
Research Absci Corp (ABSI) on Bullrun: market cap USD 1.65B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABSI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.65B
- Financial periodQ1 2026
- RevenueUSD 215.00K
- Net income-USD 118.44M
- Free cash flow-USD 98.51M
Valuation Snapshot
latest market cap is USD 1.65B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.80M | -USD 115.18M | -USD 94.03M | n/a | -0.84 | USD 20.03M | USD 5.30M | USD 189.45M |
| FY2024 | USD 4.53M | -USD 103.11M | -USD 72.81M | n/a | -0.94 | USD 41.21M | USD 3.99M | USD 179.13M |
| FY2023 | USD 5.72M | -USD 110.57M | -USD 65.50M | n/a | -1.2 | USD 72.36M | USD 7.92M | USD 176.18M |
| FY2022 | USD 5.75M | -USD 104.90M | -USD 97.51M | n/a | -1.15 | USD 59.96M | USD 10.93M | USD 274.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.65B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 528.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 302.25M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 390.34M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 194.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 759.71M | n/a | n/a | n/a |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Absci Corp's market cap?
Absci Corp's market capitalization is USD 1.65B.
What does Absci Corp do?
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.